Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | SCN3A | Q9NY46 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | MC4R | P32245 | 1/20 | 0.46 |
| ▸ | SCN4A | P35499 | 1/20 | 0.46 |
| ▸ | MC3R | P41968 | 1/20 | 0.46 |
| ▸ | HTR3A | P46098 | 1/20 | 0.46 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.41 |
| ▸ | TOP2A | P11388 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | SCN1A | P35498 | 2/20 | 0.40 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29352729 | 0.83 | CA12 (0.50) | LMNAMAPTSCN3AALDH1A1CYP3A4 | |
| SCHEMBL9830020 | 0.79 | TOP2A (0.61) | ALDH1A1NLRP3TOP2A | |
| SCHEMBL28040969 | 0.78 | ITGB3 (0.50) | LMNAMAPTSCN3AALDH1A1CYP3A4 | |
| SCHEMBL11676642 | 0.77 | ALDH1A1 (0.51) | LMNAMAPTALDH1A1MAPK1MEN1 | |
| SCHEMBL1842965 | 0.76 | HDAC3 (0.44) | LMNAMAPTSCN3AALDH1A1CYP3A4 | |
| SCHEMBL27691961 | 0.75 | TOP2A (0.46) | LMNAMAPTALDH1A1NLRP3TOP2A | |
| SCHEMBL11311241 | 0.73 | TOP2A (0.63) | MAPTALDH1A1CYP3A4NLRP3TOP2A | |
| SCHEMBL29939966 | 0.73 | MAPT (0.53) | LMNAMAPTALDH1A1MAPK1GAA | |
| SCHEMBL5840221 | 0.72 | MAPT (0.54) | LMNAMAPTSCN3AALDH1A1CYP3A4 | |
| SCHEMBL29940096 | 0.72 | HSD17B10 (0.50) | ALDH1A1MAPK1HDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12258335-B1 | Matrix metalloproteinase (MMP) inhibitors and methods of use thereof | FORESEE PHARMACEUTICALS USA, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| CN-119462623-A | Matrix Metalloproteinase (MMP) inhibitors and methods of use thereof | 逸达生物科技美国公司 | 2025-02-18 | — | — | CN | disclosed |
| US-20250051434-A1 | MONOVALENT INTERLEUKIN 12 (IL-12) HETERODIMERIC FC PROTEINS | MERCK SHARP & DOHME LLC (US) | 2025-02-13 | — | — | US | disclosed |
| CN-112424192-B | Matrix Metalloproteinase (MMP) inhibitors and methods of use thereof | 逸达生物科技美国公司 | 2024-11-26 | — | — | CN | disclosed |
| US-20240228579-A1 | FC MUTANT WITH ALTERED BINDING TO FC RECEPTOR | INNOVENT BIOLOGICS (SUZHOU) CO., LTD. (CN) | 2024-07-11 | — | — | US | disclosed |
| EP-4349332-A2 | MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF | Foresee Pharmaceuticals USA, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-4335868-A1 | FC MUTANT WITH ALTERED BINDING TO FC RECEPTOR | Innovent Biologics (Suzhou) Co., Ltd. (CN) | 2024-03-13 | — | — | EP | disclosed |
| EP-3793995-B1 | MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF | FORESEE PHARMACEUTICALS USA INC (US) | 2024-01-10 | — | — | EP | disclosed |
| WO-2022233320-A1 | FC MUTANT WITH ALTERED BINDING TO FC RECEPTOR | 信达生物制药(苏州)有限公司 | 2022-11-10 | — | — | WO | disclosed |
| US-20220228180-A1 | Methods for production of strictosidine aglycone and monoterpenoid indole alkaloids | DANMARKS TEKNISKE UNIVERSITET (DK) | 2022-07-21 | — | — | US | disclosed |
| CN-114245826-A | Method for producing strictoside and monoterpene indole alkaloid | 丹麦科技大学 | 2022-03-25 | — | — | CN | disclosed |
| EP-3969603-A1 | METHODS FOR PRODUCTION OF STRICTOSIDINE AGLYCONE AND MONOTERPENOID INDOLE ALKALOIDS | Danmarks Tekniske Universitet (DK) | 2022-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051434-A1 | MONOVALENT INTERLEUKIN 12 (IL-12) HETERODIMERIC FC PROTEINS | IL2RA, IL2, FCGR2A | LMNA 4876/4885MAPT 3494/4885SCN3A 3255/4885 |
| US-12258335-B1 | Matrix metalloproteinase (MMP) inhibitors and methods of use thereof | MMP12, MMP1, MMP11 | LMNA 1041/4885MAPT 3677/4885SCN3A 2652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.